2. Временные методические рекомендации. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19) 13-е изд., Москва: Министерство здравоохранения Российской Федерации, 2021. 231 c.

3. Pinto D., Park YJ., Beltramello M., et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature. 2020;583:290–95. Doi: 10.1038/s41586-020-2349-y.

4. GSK COVID Contact Center.

5. ClinicalTrials.gov is a database The National Library of Medicine (NLM) at the National Institutes of Health (NIH)

6. Anil Gupta M.D., Gonzalez-Rojas Y., et al. Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab. N Engl J Med. 2021;27. Doi: 10.1056/NEJMoa2107934.

7. Laurini E., Marson D., Aulic S., et al. Molecular rationale for SARS-CoV-2 spike circulating mutations able to escape bamlanivimab and etesevimab monoclonal antibodies. Sci Rep. 2021;11(1):20274. Doi: 10.1038/s41598-021-99827-3.

8. Gottlieb R.L., Nirula A., Chen P., et al. Effect of Bamlanivimab as Monotherapy or in Combination WithEtesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial. JAMA. 2021;325(7):632–44.

9. Huai-rong Xiang, Bei He, Yun Li, et al. The efficacy and safety of bamlanivimab treatment against COVID-19: A meta-analysis medRxiv. 2021.08.24.21262580. Doi: 10.1101/2021.08.24.21262580.

10. Choudhary M.C., Kara W. Chew et al. Emergence of SARS-CoV-2 Resistance with Monoclonal Antibody Therapy, for the ACTIV-2/A5401 Study Team medRxiv 2021.09.03.21263105. Doi: /10.1101/2021.09.03.21263105.

11. Sabin A.P.,. Richmond C.S., Kenny P.A. Acquisition and onward transmission of a SARS-CoV-2 E484K variant among household contacts of a bamlanivimab-treated patient. medRxiv. 2021.10.02.21264415. Doi: 10.1101/2021.10.02.21264415.

12. Bierle D.M., Ganesh R., Tulledge-Scheitel S., et al. Monoclonal Antibody Treatment of Breakthrough COVID-19 in Fully Vaccinated Individuals with High-Risk Comorbidities Razonable. medRxiv. 2021.10.19.21265222. Doi: 10.1101/2021.10.19.21265222.

13. FDA News events. Coronavirus (COVID-19) Update: FDA Authorizes Additional Monoclonal Antibody for Treatment of COVID-19. Published: May 26, 2021. URL: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-monoclonal-antibody-treatment-covid-19

14. EMA news. EMA issues advice on use of sotrovimab (VIR-7831) for treating COVID-19. Published: 21/05/2020. URL: https://www.ema.europa.eu/en/news/ema-issues-advice-use-sotrovimab-vir-7831-treating-covid-19

15. The Therapeutic Goods Administration (TGA) is Australia’s regulatory authority for therapeutic goods. News & public notices, Published: 20.08.2021. TGA provisionally approves GlaxoSmithKline’s COVID-19 treatment: sotrovimab (XEVUDY). URL: https://www.tga.gov.au/media-release/tga-provisionally-approves-glaxosmithklines-covid-19-treatment-sotrovimab-xevudy

16. FDA, Coronavirus Disease 2019 (COVID-19) EUA Information

17. FDA, Coronavirus Disease 2019 (COVID-19) EUA Information

18. FDA, Coronavirus Disease 2019 (COVID-19) EUA Information